This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.
Hemophagocytic lymphohistiocytosis (HLH) is a critical condition characterized by the undue activation of cytotoxic T lymphocytes, natural killer cells, and macrophages, resulting in excessive secretion of infammatory cytokines. Infection is an important trigger for HLH. This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Carrimycin tablets are administered 400mg a day orally for 7 days.
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Cure rates of infections
The percentage of participants having clinical cure
Time frame: 1 week and 2 weeks after initiation of treatment
Overall response rate of HLH
Overall response rate includes complete remission (CR) and partial remission (PR)
Time frame: 2 weeks after treatment
Overall Survival
OS will be assessed from initiation of treatment to death from any cause
Time frame: 1 years
Incidence and Severity of Adverse Events
Treatment-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.